| Species |
Human |
| Protein Construction |
BCMA/TNFRSF17 (Met1-Ala54)
Accession # Q02223-1 |
His |
Avi |
| N-term |
|
C-term |
|
| Purity |
> 95% as determined by Bis-Tris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Immobilized BCMA/TNFRSF17, His & Avi, Human (Cat.No.: Z03846) at 1 μg/ml (100μl/Well) on the plate can bind Biotinylated Human BAFF, His Tag. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
8.9 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 12 kDa and 15-17 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from a 0.22 μm filtered solution in PBS, pH 7.4. |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
BCMA (B-cell maturation antigen), also called TNFRSF17, is encoded by the TNFRSF17 gene. It acts as a cell surface receptor of the TNF receptor superfamily. BCMA recognizes B-cell activating factor (BAFF). It interacts with the B-cell activating factor TNFSF13B. |
| Synonyms |
CD269; TNFRSF17; BCMA; BCM; TNFRSF13A |
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.
